Browsing Tag
AGAMREE
2 posts
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
AGAMREE wins Swissmedic approval, positioning Santhera for broader Duchenne muscular dystrophy market expansion
Santhera wins Swissmedic approval for AGAMREE in Duchenne muscular dystrophy. Find out how this milestone could drive European expansion and investor sentiment.